PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR

烷基化醌和硝基芳基的光敏还原和 DNA 烷基化

基本信息

  • 批准号:
    7381559
  • 负责人:
  • 金额:
    $ 18.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2006
  • 资助国家:
    美国
  • 起止时间:
    2006-08-01 至 2007-07-31
  • 项目状态:
    已结题

项目摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Photodynamic therapy (PDT) is a cancer treatment that uses a combination of red laser light, a photosensitizing agent and molecular oxygen to bring about a therapeutic effect. PDT is particularly promising for treating hollow-organ cancers, for example oesophageal cancers. This is because laser light can now be delivered with great accuracy, via thin flexible optical fibers and endoscopy, to almost any site in the body and with minimal damage to overlying healthy tissue. Porphyrins (POR), phthalocyanines (PC), chlorins (CHL) and others are currently being used in photodynamic treatment (PDT) of tumors due to their large absorption coefficients in the 500-800 nm range. In the presence of air these will photosensitize the production of singlet oxygen and superoxide. Singlet oxygen production, the so-called Type II pathway, is claimed as the most important process which kills tumor cells. However, Type I pathways, those involving photoreduction or photooxidation of substrates, have.also been proposed as photocytotoxic events in PDT, especially in hypoxic environments. In addition, PDT produces in many instances, in cells, apoptosis and necrosis. Solid tumors are often hypoxic. Thus, if photosensitizers are localized inside these tumors, singlet oxygen would not be the reactive species which should eventually kill these tumor cells. Since these dyes are able to photoreduce oxygen, then, these should also photoreduce molecules with nearly equal or more positive redox potentials than oxygen in anoxic/hypoxic cells. If this substrate is a DNA alkylating quinone or nitroarene, which is activated by reduction, it could act as an alkylating species and then DNA alkylation should be expected, with the consequent cell death. Such activation should occur near the DNA site to avoid wasting quinones or nitroarenes by alkylation of other less critical macromolecules. Nitroarenes are reduced to nitrosoarenes (2 electrons), which are highly reactive towards thiols, or further to hydroxylamines (4 electrons), which are reactive species towards Lguanine. In contrast, the aziridinyl-quinones require either 1 or 2 electrons to be activated as alkylating agents. In this regard, since fewer electrons are needed by quinones for alkylating activity aziridinyl-quinones could be more easily photoactivated to a DNA-alkylating species. Photosensitizers are photooxidized, or their triplet states quenched, by nitroimidazoles under anaerobic and hypoxic conditions. This has been demonstrated using flash photolysis methods, even for a nitroimidazole with a much more negative redox potential than oxygen. For example, this was observed using hematoporphyrin and uroporphyrin as photosenzitizers in the presence of metronidazole, with E = -485 mV, while the redox potential of oxygen is -330 mV. However, to our best knowledge, direct detection and characterization of a dye-photoreduced nitroarene or quinone has not occurred. To our best knowledge, previous work on reactions involving photosensitizers and nitroarenes (a) have not dealt with cells under hypoxic conditions, (b) have not considered the importance of the nitroarene redox potential in the yield or quantum yields of photoreduction or cytotoxicity, (c) have not used alkylating quinones instead of nitroaranes in their studies, (d) have not considered the yields or quantum yields of reduced quinone/nitroarene in heterogeneous media vs. aqueous media and (e) have not explored the combination of a DNA-bound (or free) sensitizer with an alkylating quinonelnitroarene in producing DNA adducts. In this work, pyridinium zinc phthalocyanine (PPC) and 5,10,15,20-tetrakis(1-methyl-4-pyridinio)porphyrin tetra(p-toluenesulfonate) (TMPyP), which are cations and should bind DNA phosphates, will always be included in the development of the following specific aims. Other photosensitizers (hydrophilic or lipophylic and negatively charged) will be included for comparative purposes. Whenever possible, the role of pH will be determined. Special emphasis will also be made on hypoxic or anoxic conditions, although normoxic conditions will be used for comparison. Thus, the following specific aims are designed to fill some of the gaps stated above: 1. To measure binding or distribution constants of POR, PC, CHL and quinones and nitroarenes to DNA or oligonucleotides and multilamellar vesicles (MLVs) of dimiristoylphosphatidylcholine (DMPC) in order to determine the relative hydrophobicity and amount of the photosensitizer and quinone/nitroarene bound to DNA or lipid membrane. 2. To detect intermediates in the photoreactions of POR, PC and CHL in the presence or absence of quinone/nitroarenes and in the presence or absence of nucleosides (guanosine, adenosine). 3. To detect intermediates in the photoreactions of DNA-bound (or oligonucletide-bound), lipid SUVs (small unilamellar vesicles)-bound, and unbound POR, PC and CHL with quinone/nitroarenes. 4. To measure photophysical properties of these intermediates and the interdependence of these properties on the physical properties of the photosensitizer and substrate (redox potentials of substrates, triplet energy of the sensitizer, DNA binding, lipid partition). 5. To identify and quantify photoproducts derived from the quinone/nitroarenes in the photoreactions stated above, in the presence and absence of SUVs or DNA, not including DNA covalent adducts. 6. To identify nucleoside and DNA covalent adducts, including cross-linking, formed in the photoreactions described above. 7. To determine the role of the combination of these photosensitizers with alkylating quinones/nitroarenes on inducing cytotoxicity in tumor cells under hypoxia/anoxia vs.normoxia. Specific aim # 7 will test pairs of sensitizers and quinone/nitroarenes which are successful in the production of intermediates or photoproducts under anoxia or hypoxia measured in Specific Aims 2 to 6. A few of the unsuccessful pairs will also be included as negative controls. Specific Aims 1 and 2 will be worked on during the first years. The rest of the years will essentially be devoted to specific Aims 3 to 7.

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ANTONIO E ALEGRIA其他文献

ANTONIO E ALEGRIA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ANTONIO E ALEGRIA', 18)}}的其他基金

REDUCTIVE AND PHOTOSENSITIZED ACTIVATION OF TUMOR-TARGETED QUINONES
肿瘤靶向醌的还原和光敏激活
  • 批准号:
    8360148
  • 财政年份:
    2011
  • 资助金额:
    $ 18.24万
  • 项目类别:
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR
烷基化醌和硝基芳基的光敏还原和 DNA 烷基化
  • 批准号:
    8167848
  • 财政年份:
    2010
  • 资助金额:
    $ 18.24万
  • 项目类别:
UPRH Biomedical Research Improvement Program
UPRH 生物医学研究改进计划
  • 批准号:
    7982352
  • 财政年份:
    2009
  • 资助金额:
    $ 18.24万
  • 项目类别:
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR
烷基化醌和硝基芳基的光敏还原和 DNA 烷基化
  • 批准号:
    7960047
  • 财政年份:
    2009
  • 资助金额:
    $ 18.24万
  • 项目类别:
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR
烷基化醌和硝基芳基的光敏还原和 DNA 烷基化
  • 批准号:
    7720861
  • 财政年份:
    2008
  • 资助金额:
    $ 18.24万
  • 项目类别:
Quinone Roles in NO Reduction & Production Enhancements & Tumor-Targeted Toxicity
醌在 NO 还原中的作用
  • 批准号:
    7288961
  • 财政年份:
    2007
  • 资助金额:
    $ 18.24万
  • 项目类别:
ADMINISTRATIVE CORE
行政核心
  • 批准号:
    7508865
  • 财政年份:
    2007
  • 资助金额:
    $ 18.24万
  • 项目类别:
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR
烷基化醌和硝基芳基的光敏还原和 DNA 烷基化
  • 批准号:
    7610155
  • 财政年份:
    2007
  • 资助金额:
    $ 18.24万
  • 项目类别:
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROARE
烷基化醌和硝基的光敏还原和 DNA 烷基化
  • 批准号:
    7170783
  • 财政年份:
    2005
  • 资助金额:
    $ 18.24万
  • 项目类别:
Reduction of Alkylating Quinones and Nitroarenes
烷基化醌和硝基芳烃的还原
  • 批准号:
    6656764
  • 财政年份:
    2003
  • 资助金额:
    $ 18.24万
  • 项目类别:

相似国自然基金

兼捕减少装置(Bycatch Reduction Devices, BRD)对拖网网囊系统水动力及渔获性能的调控机制
  • 批准号:
    32373187
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目

相似海外基金

The Impact of a Race-Based Stress Reduction Intervention on Well-Being, Inflammation, and DNA methylation in Older African American Women at Risk for Cardiometabolic Disease
基于种族的减压干预措施对有心血管代谢疾病风险的老年非洲裔美国女性的健康、炎症和 DNA 甲基化的影响
  • 批准号:
    10633624
  • 财政年份:
    2023
  • 资助金额:
    $ 18.24万
  • 项目类别:
Reduction of immunogenicity of SARS-CoV-2 vaccine in the elderly people: analysis by DNA methylation
老年人 SARS-CoV-2 疫苗免疫原性的降低:DNA 甲基化分析
  • 批准号:
    22K07447
  • 财政年份:
    2022
  • 资助金额:
    $ 18.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Effect of antioxidans on the reduction of DNA toxicity caused by intermediates and eluates from commercially available and experimental dental restorative materials
抗氧化剂对降低市售和实验牙科修复材料中间体和洗脱物引起的 DNA 毒性的影响
  • 批准号:
    315677466
  • 财政年份:
    2016
  • 资助金额:
    $ 18.24万
  • 项目类别:
    Research Grants
Reduction of DNA fragmentation of freeze-dried boar sperm and elucidation of the repair mechanism for piglet production
减少冻干公猪精子DNA碎片并阐明仔猪生产的修复机制
  • 批准号:
    26450462
  • 财政年份:
    2014
  • 资助金额:
    $ 18.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats
血管紧张素 II DNA 疫苗长期降低自发性高血压大鼠的高血压
  • 批准号:
    26461250
  • 财政年份:
    2014
  • 资助金额:
    $ 18.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Induction and reduction of DNA toxicity caused by intermediates from dental restorative ma-terials
牙科修复材料中间体引起的 DNA 毒性的诱导和减少
  • 批准号:
    255951300
  • 财政年份:
    2014
  • 资助金额:
    $ 18.24万
  • 项目类别:
    Research Grants
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR
烷基化醌和硝基芳基的光敏还原和 DNA 烷基化
  • 批准号:
    8167848
  • 财政年份:
    2010
  • 资助金额:
    $ 18.24万
  • 项目类别:
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR
烷基化醌和硝基芳基的光敏还原和 DNA 烷基化
  • 批准号:
    7960047
  • 财政年份:
    2009
  • 资助金额:
    $ 18.24万
  • 项目类别:
PHOTOSENSITIZED REDUCTION AND DNA ALKYLATION OF ALKYLATING QUINONES AND NITROAR
烷基化醌和硝基芳基的光敏还原和 DNA 烷基化
  • 批准号:
    7720861
  • 财政年份:
    2008
  • 资助金额:
    $ 18.24万
  • 项目类别:
What kind of DNA sequences is involved in chromosome size reduction in genus Aster?
什么样的 DNA 序列参与紫菀属染色体尺寸的减小?
  • 批准号:
    20570099
  • 财政年份:
    2008
  • 资助金额:
    $ 18.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了